How much cash does BridgeBio Pharma generate?

BridgeBio Pharma (BBIO) generated -$444.0M in operating cash flow over the trailing twelve months.

What is BridgeBio Pharma's free cash flow?

After $1.2M of capital expenditures, BridgeBio Pharma's free cash flow was -$445.1M over the trailing twelve months, up 44.0% year over year.

Where does BridgeBio Pharma's cash flow data come from?

Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

BridgeBio Pharma BBIO Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$729.89M-7.8%	-$732.94M-34.9%	-$805.69M-80.5%	-$785.01M-70.1%	-$676.8M-23.8%
Depreciation and amortization	$5.34M-7.4%	$5.43M-10.6%	$5.37M-14.7%	$5.51M-13.9%	$5.76M-10.7%
Stock-based compensation	$140.38M+34.2%	$133.02M+38.9%	$128.51M+25.1%	$120.41M+22.7%	$104.63M+0.7%
Amortization of debt issuance costs	——	——	——	——	——
Change in accounts receivable	——	——	——	——	-$120.23M-154%
Change in inventories	$29.17M+813%	$25.31M—	$23.36M—	$16.58M—	$3.19M—
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	$4.91M-61.0%	$23.02M+35.5%	$14.62M-16.6%	$9.73M—	$12.59M—
Change in other assets	——	——	——	——	——
Change in other liabilities	$79.48M+847%	$77.81M+1,757%	$63.83M+1,213%	$31.89M+4,670%	$8.39M+507%
Other working capital changes	——	——	——	——	——
Change in deferred revenue	-$11.24M—	-$11.43M—	-$8.18M—	——	——
Net gains (losses) on investments	-$2.73M—	$0—	——	——	——
Non-cash operating lease expense	——	——	——	——	——
Loss on extinguishment of debt	$0+100%	-$21.16M+20.4%	-$21.16M+20.4%	-$21.16M+20.4%	-$21.16M+20.4%
Change in operating lease liabilities	-$6.93M-19.9%	-$6.55M-10.9%	-$6.2M-10.4%	-$6.04M-12.5%	-$5.78M-11.7%
Net cash from operating activities	-$443.95M—	-$445.91M—	-$584.82M—	-$655.81M—	——
Capital expenditures	$1.17M+390%	$1.1M+17.6%	$1.11M-15.9%	$778K-51.8%	$238K-88.0%
Purchases of investments	——	——	——	——	$70.36M+53.8%
Proceeds from maturities/sales of investments	$12.3M—	$2.3M—	——	——	——
Purchases of intangible assets	$6.9M-21.3%	$8.5M+6.5%	$11.69M+144%	$10.88M+241%	$8.77M+1,001%
Net cash from investing activities	——	——	——	$23.63M-62.8%	$39.67M-38.5%
Repurchases of common stock	——	——	——	——	$48.28M—
Proceeds from issuance of debt	——	——	——	——	——
Repayments of debt	——	——	——	——	——
Proceeds from issuance of common stock	$22.59M—	$0—	——	——	——
Distributions to noncontrolling interests	——	——	——	——	——
Taxes paid for net share settlement	$16.52M+160%	$14.23M+89.0%	$8.2M-5.5%	$6.62M-32.8%	$6.37M-31.6%
Payment of debt issuance costs	——	——	——	——	——
Net cash from financing activities	——	——	——	$837.01M—	$534.97M—
Net increase (decrease) in cash	$339.28M—	-$111.1M—	$237.22M—	——	——
Interest paid	——	——	——	——	$79.3M+6.6%
Non-cash interest expense	——	——	——	——	——
Deconsolidation Gain (Loss), Amount, Including Adjustments	——	$0-100%	$44.58M-66.6%	$89.16M+0.7%	$133.74M+206%
Change in fair value of the conversion option of the convertible senior notes	——	——	——	——	——
Equity in earnings (losses) of equity method investees	-$75.34M-61.2%	-$72.61M-133%	-$68.27M-371%	-$59M-645%	-$46.74M—
Accrued research and development liabilities	$20.8M—	$7.16M—	——	——	——
Deferred revenue	-$11.24M—	-$11.43M—	-$8.18M—	——	——
Accrued compensation and employee benefits	$4.91M-61.0%	$23.02M+35.5%	$14.62M-16.6%	$9.73M—	$12.59M—
Operating lease liabilities	-$6.93M-19.9%	-$6.55M-10.9%	-$6.2M-10.4%	-$6.04M-12.5%	-$5.78M-11.7%
Increase (Decrease) in Other Operating Assets	$2.27M+185%	-$1.11M+27.8%	-$2.54M-174%	-$426K-167%	-$2.69M-534%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Noncash interest expense on deferred royalty obligations	$140.99M—	$125.14M—	$94.76M—	$58.35M—	——
Operating lease right-of-use asset amortization	——	——	——	——	——
Other Noncash Income (Expense)	——	——	——	——	——
Payment-in-kind interest	——	$0—	$0-100%	$0-100%	$0-100%
Payments to Acquire Intangible Assets	$6.9M-21.3%	$8.5M+6.5%	$11.69M+144%	$10.88M+241%	$8.77M+1,001%
Proceeds From Sale And Maturity Of Available For Sale Securities	——	——	——	——	$71.25M-16.8%
Repayments of deferred royalty obligations	——	——	——	——	——
Proceeds From Payments To Minority Shareholders	——	——	——	——	——
Proceeds from issuance of common stock relating to employee stock plans	——	——	——	——	——
Accrued payables for capital expenditures	-$282K-152%	$43K-84.6%	$17K—	$209K—	$546K—
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction	——	——	——	——	——
Transfers to noncontrolling interests	-$6.73M-40.5%	-$5.59M+3.9%	-$5.83M+15.9%	-$5.53M+15.2%	-$4.79M+49.9%
Recognized intangible asset recorded to “Other current liabilities”	——	——	——	——	——
Free cash flow	-$445.12M—	-$447.01M—	-$585.93M—	-$656.59M—	——
Free cash flow	-$445.12M—	-$447.01M—	-$585.93M—	-$656.59M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about BridgeBio Pharma.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does BridgeBio Pharma generate?: BridgeBio Pharma (BBIO) generated -$444.0M in operating cash flow over the trailing twelve months.
What is BridgeBio Pharma's free cash flow?: After $1.2M of capital expenditures, BridgeBio Pharma's free cash flow was -$445.1M over the trailing twelve months, up 44.0% year over year.
Where does BridgeBio Pharma's cash flow data come from?: Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.